Article

Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study

University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany
Journal of Hepatology (Impact Factor: 10.4). 11/2005; 43(4):590-8. DOI: 10.1016/j.jhep.2005.04.007
Source: PubMed

ABSTRACT The natural course of the hepatitis C virus genotype 1b (HCV-1b) infection is still unclear but important for therapeutic decisions. There are few unbiased long-term follow-up studies with known dates of infection.
Between August 1978 and March 1979, 14 HCV-1b contaminated batches of anti-D immunoglobulin had been administered to 2867 women for prophylaxis of rhesus isoimmunization throughout East Germany. We reexamined 1980 women, representing 70% of the total cohort of 15 centers.
After application of the contaminated anti-D, 93% of the recipients developed an acute hepatitis C. After 25 years, 86% of the 1833 affected women still tested positive for hepatitis C virus antibodies and 46% for HCV RNA. Only nine (0.5%) had overt liver cirrhosis, 30 women (1.5%) developed pre-cirrhotic stages and one HCC was diagnosed. Ten (0.5%) died of HCV related complications, half of these related to additional comorbidity. In the last 5 years, a continuous, but low increase of fibrotic scores was observed.
Young women without comorbidity may clear HCV (1b) infection in more than half of the cases, or develop mild chronic hepatitis C. We confirmed the low risk of progression to cirrhosis in this cohort within 25 years.

Download full-text

Full-text

Available from: Manfred Wiese, Aug 22, 2014
1 Follower
 · 
124 Views
  • Source
    • "Studies published over the last two decades showed remarkably different findings concerning the incidence of liver cirrhosis. While very low rates of cirrhosis were reported in special cohorts like young women infected in the late 1970s [55], life-time prevalence liver cirrhosis was estimated as up to 69% in hospital-based settings [56]. Table 1 gives an overview of results obtained in selected studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) infection remains a major global health burden. Hepatitis C causes significant liver-related morbidity and mortality due to hepatic decompensation and development of hepatocellular carcinoma. In addition, extra-hepatic manifestations of hepatitis C are frequent. There is a very large interindividual variability in the natural history of both acute and chronic hepatitis C which can be explained in part by a combination of various host, viral and environmental factors. Successful antiviral treatment can prevent short- and long-term complications of HCV infection in many patients. Still, the relative contribution of distinct risk factors for disease progression in different phases of HCV infection needs to be better defined. Personalized treatment approaches for HCV infection should consider individual risk profiles to avoid both under- and over-treatment - which will remain important also in upcoming era of interferon-free treatment of hepatitis C.
    Best practice & research. Clinical gastroenterology 08/2012; 26(4):401-12. DOI:10.1016/j.bpg.2012.09.009 · 3.28 Impact Factor
  • Source
    • "Now, more than 20 years later, it is well known from studies of the natural course of HCV infection that the development of severe liver disease is less frequent than initially feared: specifications of the lifetime prevalence of severe liver disease after HCV infection range between 0.4% and 8% (Hoofnagle, 2002; Wiese et al, 2005). It also became obvious that severe chronic fatigue, which affects B50% of the patients, is the most frequent disabling complication of HCV infection (Wiese et al, 2005; Poynard et al, 2002). A growing number of studies have shown cognitive dysfunction besides chronic fatigue and mood alterations in HCV-infected patients with only mild liver disease (Forton et al, 2001, 2002; Weissenborn et al, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with hepatitis C virus (HCV) infection frequently show neuropsychiatric symptoms. This study aims to help clarify the neurochemical mechanisms behind these symptoms and to add further proof to the hypothesis that HCV may affect brain function. Therefore, 15 patients who reported increasing chronic fatigue, mood alterations, and/or cognitive decline since their HCV infection underwent neurologic and neuropsychological examination, magnetic resonance imaging, (18)F-fluoro-deoxy-glucose positron emission tomography of the brain, and single photon emission tomography of striatal dopamine and midbrain serotonin transporter (SERT) availability. None of the patients had liver cirrhosis. Patients' data were compared with data of age-matched controls. In addition, regression analysis was performed between cognitive deficits, and mood and fatigue scores as dependent variables, and cerebral glucose metabolism, dopamine, or SERT availability as predictors. Patients showed significant cognitive deficits, significantly decreased striatal dopamine and midbrain SERT availability, and significantly reduced glucose metabolism in the limbic association cortex, and in the frontal, parietal, and superior temporal cortices, all of which correlated with dopamine transporter availability and psychometric results. Thus, the study provides further evidence of central nervous system affection in HCV-afflicted patients with neuropsychiatric symptoms. Data indicate alteration of dopaminergic neurotransmission as a possible mechanism of cognitive decline.
    Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 06/2011; 31(11):2199-208. DOI:10.1038/jcbfm.2011.82 · 5.34 Impact Factor
  • Source
    • "We had access to the exact date of HCV diagnosis, but not the date of HCV-infection [6]. For a substantial proportion of study participants, HCV-infection could have preceded study inclusion by several years, since most HCVinfections occur subclinically [6]. Thus patients in the chronic group could have had more liver damage at the time of study inclusion than patients in the cleared group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is unknown whether mortality differs between patients with chronic hepatitis C virus (HCV) replication and those who cleared the virus after infection. We examined the impact of chronic HCV replication on mortality among Danish patients testing positive for HCV antibodies. This nationwide cohort study focused on Danish patients with at least one HCV RNA measurement available after testing positive for HCV antibodies between 1996 and 2005. To capture long-term prognosis, eligible patients needed to be alive 1year after HCV RNA assessment. We estimated mortality rate ratios (MRRs) using Cox regression (for overall mortality) and subdistribution hazard ratios (SDHRs) for cause-specific mortality, controlling for gender, age, comorbidity, calendar period, alcohol abuse, injection drug use, and income. Of the 6292 patients under study, 63% had chronic HCV-infection and 37% had cleared the virus. Five-year survival was 86% (95% confidence interval (CI): 84-87%) in the chronic HCV group and 92% (95% CI: 91-94%) in the cleared HCV group. Chronic HCV-infection was associated with higher overall mortality (MRR: 1.55, 95% CI: 1.28-1.86) and liver-related death (SDHR: 2.42, 95% CI: 1.51-3.88). Chronic HCV-infection greatly increased the risk of death from primary liver cancer (SDHR: 16.47, 95% CI: 2.24-121.00). Patients with chronic HCV-infection are at higher risk of death than patients who cleared the infection. The substantial association found between chronic HCV-infection and death from primary liver cancer supports early initiation of antiviral treatment in chronically HCV-infected patients.
    Journal of Hepatology 07/2010; 53(1):36-42. DOI:10.1016/j.jhep.2010.01.033 · 10.40 Impact Factor
Show more